免疫组化检测63例原发甲状腺癌中BRAF突变及其价值研究

被引:9
作者
冯勤 [1 ]
李忠武 [1 ]
刘卉 [1 ]
周立新 [1 ]
池海谊 [2 ]
刘毅 [3 ]
机构
[1] 北京大学肿瘤医院暨北京市肿瘤防治研究所病理科恶性肿瘤发病机制及转化研究教育部重点实验室
[2] 内蒙古呼和浩特市第一医院内分泌科
[3] 内蒙古呼和浩特市第一医院病理科
关键词
甲状腺乳头状癌; BRAF V600E突变;
D O I
暂无
中图分类号
R736.1 [甲状腺肿瘤];
学科分类号
100112 [医学生物化学与分子生物学];
摘要
<正>甲状腺乳头状癌是最为常见的甲状腺恶性肿瘤。BRAFV600E突变是甲状腺乳头状癌中最为常见的基因突变之一。据报道,45%的甲状腺乳头状癌病例会出现BRAFV600E基因突变[1]。BRAFV600E的突变对于甲状腺乳头状癌的确诊以及预测不良预后非常重要。目前可用于BRAFV600E突变的检测方法有Sanger测序法、焦磷酸测序高分辨率熔解曲线分析及等位基因特异扩增(PCR)等方法[1]。
引用
收藏
页码:1188 / 1190
页数:3
相关论文
共 10 条
[1]
BRAF基因V600E突变在甲状腺病变中的表达[J] 王炜;黎向红;章银辉;李兢;陈珏;赵盼;李巧云;项晶晶;李晓;徐如君; 中华肿瘤杂志 2011, 05
[2]
Database and registry research in thyroid cancer: striving for a new and improved national thyroid cancer database.[J] Mehra Saral;Tuttle R Michael;Milas Mira;Orloff Lisa;Bergman Donald;Bernet Victor;Brett Elise;Cobin Rhoda;Doherty Gerard;Judson Benjamin L;Klopper Joshua;Lee Stephanie;Lupo Mark;Machac Josef;Mechanick Jeffrey I;Randolph Gregory;Ross Douglas S;Smallridge Robert;Terris David;Tufano Ralph;Alon Eran;Clain Jason;DosReis Laura;Scherl Sophie;Urken Mark L Thyroid : official journal of th
[3]
Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experience[J] Esther Diana Rossi;Maurizio Martini;Sara Capodimonti;Tonia Cenci;Patrizia Straccia;Basilio Angrisani;Costantino Ricci;Paola Lanza;Celestino Pio Lombardi;Alfredo Pontecorvi;Luigi Maria Larocca;Guido Fadda Cancer Cytopathology 2014,
[4]
The prognostic significance of the BRAFV600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry[J] Penelope A. McKelvie;Fiona Chan;Yong Yu;Paul Waring;Irma Gresshoff;Stephen Farrell;Richard A. Williams Pathology 2013,
[5]
Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma; pulmonary carcinoma; gastrointestinal carcinoma; thyroid carcinoma; and gliomas[J] Caitlin Ann Routhier;Mark C. Mochel;Kerry Lynch;Dora Dias-Santagata;David N. Louis;Mai P. Hoang Human Pathology 2013,
[6]
Evaluation of BRAF Mutation Testing Methodologies in Formalin-Fixed; Paraffin-Embedded Cutaneous Melanomas[J] Johanne Lade-Keller;Kirsten M. Rømer;Per Guldberg;Rikke Riber-Hansen;Lise Lotte Hansen;Torben Steiniche;Henrik Hager;Lasse S. Kristensen The Journal of Molecular Diagnostics 2013,
[7]
Immunohistochemical testing of BRAF V600E status in 1;120 tumor tissue samples of patients with brain metastases[J] Acta Neuropathologica 2012,
[8]
Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH[J] Eunhee S. Yi;Jennifer M. Boland;Joseph J. Maleszewski;Anja C. Roden;Andre M. Oliveira;Marie-Christine Aubry;Michele R. Erickson-Johnson;Bolette L. Caron;Yan Li;Hui Tang;Shawn Stoddard;Jason Wampfler;Kimary Kulig;Ping Yang Journal of Thoracic Oncology 2011,
[9]
Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation[J] Linwah Yip;Marina N. Nikiforova;Sally E. Carty;John H. Yim;Michael T. Stang;Mitchell J. Tublin;Shane O. LeBeau;Steven P. Hodak;Jennifer B. Ogilvie;Yuri E. Nikiforov Surgery 2009,
[10]
Guilty as charged[J] Mathew J. Garnett;Richard Marais Cancer Cell 2004,